GILD

Gilead Sciences
D

GILD

117.820
USD
1.06
(0.91%)
مفتوح الان
حجم التداول
199,684
الربح لكل سهم
8
العائد الربحي
2.69
P/E
23
حجم السوق
146,018,157,875
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 11 شهر
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).